home / stock / adilw / adilw news

ADILW News and Press, Adial Pharmaceuticals Inc Warrant From 11/29/21

Stock Information
Company Name: Adial Pharmaceuticals Inc Warrant
Stock Symbol: ADILW
Market: NASDAQ
Website: adialpharma.com
Menu
ADILW ADILW Quote ADILW Short ADILW News ADILW Articles ADILW Message Board
Get ADILW Alerts

News, Short Squeeze, Breakout and More Instantly...
ADILW - Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer

CHARLOTTESVILLE, Va., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...
ADILW - REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Clinical Update and Discuss Latest Developments

CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...

ADILW - Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options

CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...

ADILW - Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments

CHARLOTTESVILLE, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...
ADILW - Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors

CHARLOTTESVILLE, Va., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of ...

ADILW - Adial Announces Positive Pre-Clinical Data for Purnovate's PNV-5030 as a Drug Candidate for the Treatment of Pain

Results suggest potential of PNV-5030 as both a standalone and combination therapy to reduce or eliminate opioid use and achieve meaningful pain reduction Clinical trial expected to commence in 2022 CHARLOTTESVILLE, Va., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adial Pharmace...

ADILW - Adial Announces Positive Pre-Clinical Data for Purnovate's PNV-5030 as Drug Candidate for the Treatment of Pain

Results suggest potential of PNV-5030 as both a standalone and combination therapy to reduce or eliminate opioid use and achieve meaningful pain reduction Clinical trial expected to commence in 2022 CHARLOTTESVILLE, Va., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adial Pharmace...
ADILW - Adial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

CHARLOTTESVILLE, Va., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...

ADILW - Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021

CHARLOTTESVILLE, VA / ACCESSWIRE / October 5, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced tha...

ADILW - Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD(TM) Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period - Trial Completion Anticipated Q1 2022

CHARLOTTESVILLE, Va., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and...
Previous 10 Next 10